Cent Eur J Public Health 2017, 25(4):282-286 | DOI: 10.21101/cejph.a4948

Trends in the minimum inhibitory concentrations of erythromycin, clarithromycin, azithromycin, ciprofloxacin, and trimethoprim/sulfamethoxazole for strains of Bordetella pertussis isolated in the Czech Republic, 1967-2015

Vladislav Jakubů1, Jana Zavadilová1, Kateřina Fabiánová1,2, Pavla Urbášková1
1 Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
2 Institute of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic

Objective: The aim of the study was to determine trends in the minimum inhibitory concentrations (MICs) of erythromycin used as first-line therapy and alternative antibiotics against Bordetella pertussis (B. pertussis) strains isolated from patients with whooping cough in the Czech Republic (CR) in three periods from 1967 to 2015.

Methods: In total, 135 isolates from the years 1967-2015 were analysed. The strains were divided into three groups by the year of isolation: 1967-1999 (42 strains), 2004-2010 (43 strains), and 2011-2015 (50 strains). MIC of selected antibiotics (erythromycin, clarithromycin, azithromycin, ciprofloxacin, and trimethoprim/sulfamethoxazole) were obtained by the reference agar dilution method on Bordet Gengou Agar with 15% defibrinated sheep blood.

Results: The study set included 70 strains previously tested for MICs of erythromycin and four other antibiotics. In the three study periods, the MICs of the tested antibiotics for B. pertussis were nearly identical. All but a single strain, inhibited by erythromycin at a concentration of 0.03 mg/l, were inhibited by two concentrations of erythromycin and azithromycin (0.06 and 0.125 mg/l). Clarithromycin inhibited the strains from all three study periods at the following concentrations: 0.03, 0.06, and 0.125 mg/l. Any of the 135 strains was inhibited by ciprofloxacin at a single concentration of 0.06 mg/l and by trimethoprim/sulfamethoxazole at three concentrations (0.125, 0.25, and 0.5 mg/l).

Conclusion: The study set of 135 Czech strains of B. pertussis isolated in 1967-2015 appears to be homogeneous in terms of the MICs for five antimicrobials. The MICs remained in a narrow range of two to three low concentrations; the unimodal distribution of the MICs suggests the absence of resistance mechanisms. The highest MICs of erythromycin, clarithromycin, and azithromycin were equally 0.125 mg/l, that of ciprofloxacin was 0.06 mg/l, and that of trimethoprim/sulfamethoxazole was 0.5 mg/l. Over the study period of 55 years, the MICs of the study antibiotics remained in the same ranges.

Keywords: Bordetella pertussis, MIC, erythromycin, clarithromycin, azithromycin, ciprofloxacin, trimethoprim/sulfamethoxazole

Received: October 13, 2016; Revised: November 14, 2017; Published: December 30, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jakubů V, Zavadilová J, Fabiánová K, Urbášková P. Trends in the minimum inhibitory concentrations of erythromycin, clarithromycin, azithromycin, ciprofloxacin, and trimethoprim/sulfamethoxazole for strains of Bordetella pertussis isolated in the Czech Republic, 1967-2015. Cent Eur J Public Health. 2017;25(4):282-286. doi: 10.21101/cejph.a4948. PubMed PMID: 29346850.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000 Jul-Aug;6(4):348-57. Go to original source... Go to PubMed...
    2. Güriş D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999 Jun;28(6):1230-7. Go to original source... Go to PubMed...
    3. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B; Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001 Jun 15;32(12):1691-7. Go to original source... Go to PubMed...
    4. Hoppe JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection. 1998 Jul-Aug;26(4):242-6. Go to original source... Go to PubMed...
    5. Waters V, Halperin SA. Bordetella pertussis. In: Bennet JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's. Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier; 2014. p. 2619-28. Go to original source...
    6. John Hopkins POC-IT Guides [Internet]. Charlottesville: Unbound Medicine; 2014 [cited 2014 Nov 11]. Available from: http://www.hopkinsguides.com/hopkins/ub/index/Johns_Hopkins_ABX_Guide.
    7. Halsey NA, Welling MA, Lehman RM. Nosocomial pertussis: a failure of erythromycin treatment and prophylaxis. Am J Dis Child. 1980 May;134(5):521-2. Go to original source... Go to PubMed...
    8. Lewis K, Saubolle MA, Tenover FC, Rudinsky MF, Barbour SD, Cherry JD. Pertussis caused by an erythromycin resistant strain of Bordetella pertussis. Pediatr Infect Dis J. 1995 May;14(5):388-91. Go to original source... Go to PubMed...
    9. Korgenski K, Daly JA. Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West Region of the United States. J Clin Microbiol. 1997 Nov;35(11):2989-91. Go to original source... Go to PubMed...
    10. Bartkus JM, Juni BA, Ehresmann K, Miller CA, Sanden GN, Cassiday PK, et al. Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. J Clin Microbiol. 2003 Mar;41(3):1167-72. Go to original source... Go to PubMed...
    11. Yao SM, Liaw GJ, Chen YY, Yen MH, Chen YH, Mu JJ, et al. Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient. J Med Microbiol. 2008 Dec;57(Pt 12):1577-80. Go to original source... Go to PubMed...
    12. Guillot S, Descours G, Gillet Y, Etienne J, Floret D, Guiso N. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis. 2012 Jun;18(6):966-8. Go to original source... Go to PubMed...
    13. Shahcheragh F, Nakhost Lotfi MN, Nikbin VS, Shooraj F, Azizian R, Parzadeh, et al. The first macrolide-resistant Bordetella pertussis strains isolated from Iranian patients. Jundishapur J Microbiol. 2014 Jun;7(6):e10880. Go to original source... Go to PubMed...
    14. Wang Z, Cui Z, Li Y, Hou T, Liu X, Xi Y, et al. High prevalence of erythromycin-resistant Bordetella pertussis in Xi'an, China. Clin Microbiol Infect. 2014 Nov;20(11):O825-30. Go to original source... Go to PubMed...
    15. Yang Y, Yao K, Ma X, Shi W, Yuan L, Yang Y. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970-2014). PLoS One. 2015 Sep 25;10(9):e0138941. Go to original source... Go to PubMed...
    16. Ohtsuka M, Kikuchi K, Shimizu K, Takahashi N, Ono Y, Sasaki T, et al. Emergence of quinolone-resistant Bordetella pertussis in Japan. Antimicrob Agents Chemother. 2009 Jul;53(7):3147-9. Go to original source... Go to PubMed...
    17. Jakubů V, Zavadilová J, Fabiánová K, Urbášková P. Minimum inhibitory concentrations of erythromycin and other antibiotics for Czech strains of Bordetella pertussis. Epidemiol Mikrobiol Imunol. 2015 Mar;64(1):12-5.
    18. Clinical and Laboratory Standards Institute. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 9th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2012.
    19. Clinical and Laboratory Standards Institute. M22-A3. CLSI quality control for commercially prepared microbiological culture media. Approved standard. 3rd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2004.
    20. European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 6.1, valid from 2016-03-01 [Internet]. Växjö: EUCAST; 2016 [cited 2016 May 25]. Available from: http://www.eucast.org/antimicrobial_susceptibility_testing/qc_tables/.
    21. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, valid from 2016-01-01 [Internet]. Växjö: EUCAST; 2016 [cited 2016 May 30]. Available from: http://www.eucast.org/antimicrobial_susceptibility_testing/breakpoints/.
    22. Hoppe JE, Paulus T. Comparison of three media for agar dilution susceptibility testing of Bordetella pertussis using six antibiotics. Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):391-3. Go to original source...
    23. Bourgeois N, Ghnassia JC, Doucet-Populaire F. In vitro activity of fluoroquinolones against erythromycin-susceptible and -resistant Bordetella pertussis. J Antimicrob Chemother. 2003 Mar;51(3):742-3. Go to original source... Go to PubMed...
    24. Fry NK, Duncan J, Vaghji L, George RC, Harrison TG. Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method. Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1183-5. Go to original source... Go to PubMed...
    25. Hill BC, Baker CN, Tenover FC. A simplified method for testing Bordetella pertussis for resistance to erythromycin and other antimicrobial agents. J Clin Microbiol. 2000 Mar;38(3):1151-5. Go to original source... Go to PubMed...
    26. Kurzynski TA, Boehm DM, Rott-Petri JA, Schell RF, Allison PE. Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project. Antimicrob Agents Chemother. 1988 Jan;32(1):137-40. Go to original source... Go to PubMed...
    27. Sintchenko V, Brown M, Gilbert GL. Is Bordetella pertussis susceptibility to erythromycin changing? MIC trends among Australian isolates 1971-2006. J Antimicrob Chemother. 2007 Nov;60(5):1178-9. Go to original source... Go to PubMed...
    28. Zhang Q, Li M, Wang L, Xin T, He Q. High-resolution melting analysis for the detection of two erythromycin-resistant Bordetella pertussis strains carried by healthy schoolchildren in China. Clin Microbiol Infect. 2013 Jun;19(6):E260-2. Go to original source... Go to PubMed...
    29. Zhang W, Shen X, Wang Y, Chen Y, Huang M, Zeng Q, et al. Outpatient antibiotic use and assessment of antibiotic guidelines in Chinese children's hospitals. Eur J Clin Pharmacol. 2008 Aug;64(8):821-8. Go to original source... Go to PubMed...
    30. Trend of the consumption of macrolides, lincosamides and streptogramins (ATC group J01F) in the community (primary care sector) in the Czech Republic from 1998 to 2014 [Internet]. Solna: ECDC [cited 2016 Oct 16]. Available at: https://ecdc.europa.eu/en/antimicrobial-consumption/database/trend-country.

    Return to the content